Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

March 23, 2006 09:00 ET

Holmes Herbs, Inc.: Omaha Research Facility Under Construction

SCOTTSDALE, ARIZONA--(CCNMatthews - March 23, 2006) - Holmes Herbs, Inc. (OTCBB:HMHB) announced today that construction is well under way on its new clinical research facility in Omaha, Nebraska, USA. The company is working with one of the nation's best construction companies, and they are moving very quickly to meet the project deadlines. Also involved in the project are some of the leading industry suppliers in terms of medical equipment, office furnishing and computer/network infrastructure. The facility is expected to open in May, 2006 and become profitable later this year.

"It is exciting to see our new state of the art facility quickly becoming a reality. Our renovation project has a well-thought out open design that facilitates both volunteer recruiting and administrative space. My visit to the construction site this week also reinforced the very high quality of our management in charge of this project," said John Metcalfe, President of Holmes Herbs Inc.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information